AS Treatment: Tofacitinib

Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study

Objectives To compare efficacy and safety of various doses of tofacitinib, an oral Janus kinase inhibitor, with placebo in patients with active ankylosing spondylitis (AS, radiographic axial spondyloarthritis). Methods In this 16-week (12-week treatment, 4-week washout), phase II, multicentre, dose-…

Clinically Important Changes in AS with Tofacitinib

Three times as many patients on tofacitinib vs placebo had significant spine changes on MRI

Tofacitinib provides ‘meaningful reduction’ in inflammation for patients with ankylosing spondylitis

Treatment with tofacitinib improved sacroiliac joint and spine scores among patients with ankylosing spondylitis and resulted in more patients achieving minimum clinically important differences compared with placebo, according to findings presented at the American College of Rheumatology Annual Meet…

MRI Benefits Seen in AS for Xeljanz

More than 30% had clinically relevant improvement